Multifactorial Evaluation of Mesotherapy with an Innovative Hyaluronic Acid Skin Booster

Background: Mesotherapy is a skincare treatment that involves injecting small amounts of biocompatible substances, like hyaluronic acid (HA) molecules, into various layers of the skin. This method is commonly used to promote facial rejuvenation and improve skin vitality. A new mesotherapeutic HA substance has been recently produced containing cross-linked monophasic mono-densified HA spheres by the SCEDIS-MSCS technology method. Objectives: The aim of the study is to evaluate the efficacy of a novel HA skin booster using SCEDIS-MSCS technology for facial skin rejuvenation in a prospective single-arm pilot trial. Methods: A prospective single-arm pilot study was conducted including twenty female patients (mean age 45 years old), Fitzpatrick type III-IV, with “thick” oily facial skin, who were treated with a novel skin booster SCEDIS-MSCS technology with multiple superficial injections in just one session. Skin texture and pore size were evaluated using the VISIA system before and two months post-treatment, while patient satisfaction was measured via the Mesotherapy Hyaluronic Acid Skin Booster Satisfaction Scale (MHASBSS). The study employed a prospective single-arm design with statistical analysis using one-way Friedman ANOVA and Wilcoxon signed-rank tests. Baseline photos were taken before and two months after the mesotherapy treatment with the innovative hyaluronic acid injectable agent. Results: Results showed significant improvements in skin texture (P = 0.05, 12.8% reduction in roughness, SD ± 6.5) and pores (P < 0.01, 15.3% reduction in count, SD ± 7.2), with MHASBSS scores increasing from 28.5 (SD ± 4.2) to 42.3 (SD ± 3.8, P = 0.001). Conclusions: The novel HA product significantly enhanced skin appearance, with sustained effects at two months, suggesting it’s potential as an effective mesotherapy agent and warranting further investigation in larger controlled trials.